Brief: Tempest Announces Agreement With Roche To Support Advancement Of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial
10/10/2024 12:07
Oct 10 (Reuters) - Tempest Therapeutics Inc TPST.O :
* TEMPEST ANNOUNCES AGREEMENT WITH ROCHE TO SUPPORT
ADVANCEMENT OF
AMEZALPAT COMBINATION THERAPY INTO FIRST-LINE HEPATOCELLULAR
CARCINOMA PIVOTAL TRIAL
* TEMPEST THERAPEUTICS INC - ROCHE TO SUPPLY ATEZOLIZUMAB,
TEMPEST
TO LEAD STUDY
* TEMPEST THERAPEUTICS INC - RETAINS ALL RIGHTS TO AMEZALPAT
* TEMPEST THERAPEUTICS INC - PHASE 3 STUDY TO START IN Q1
2025
Source text for Eikon: ID:nGNXb9cDRY
Further company coverage: TPST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T